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S220 Poster Session IGraft versus host disease (GVHD) is a significant cause of morbid-
ity and mortality after allogeneic hematopoietic stem cell transplan-
tation. In vivo quantitative T-cell depletion using CAMPATH-1H
(anti-CD52) has been explored in an effort to prevent acute
GVHD. Recently, a regimen of total lymphoid irradiation (TLI)
and anti-thymocyte globulin (ATG) has been shown to polarize T-
cells towards an inhibitory phenotype potentially reducing the risk
for GVHD. However, these strategies may lead to impaired post-
transplant immune reconstitution, increased risk of tumor relapse
and opportunistic infection. We compared the immune recovery of
20 patients undergoing reduced intensity conditioning with low
dose CAMPATH and an initial cohort of 5 patients treated with
TLI/ATG. Conditioning with CAMPATH resulted in a significant
depletion of CD4 and CD8 T-cells in the early post-transplant pe-
riod and persistence of CD4 T-cell depletion for 6 months. Follow-
ing TLI/ATG, there was a persistent depletion of CD4 T-cells with
no significant decrease in CD8 T-cells. CAMPATH was associated
with a decrease in CD45RO+ memory T-cells in the early post-
transplant period (27.2 to 5.7%, p5 0.03). T-cell recovery in early
post-transplant following TLI/ATG was associated with a rise in
the relative percentages of naive T-cells (CD45RA+) (39 to 61.3%;
p5 0.04), central memory (CD45RO +CD62L +CCR7+) (CM)
(12 to 32.8%; p5 0.05), and a significant change in the central mem-
ory:effector memory (CD45RO +CD62L-CCR7-) (EM) ratio (0.2
to 1.0). The mean percentage of regulatory T-cells
(CD4 +CD25 + FoxP3+) rose in the early post-transplant period fol-
lowing both regimens (p\0.03). Functional analyses demonstrated
that the T-cell proliferative response to Phytohemagglutinin (PHA)
was profoundly depressed following CAMPATH with mean SI de-
creasing from 34 pre-transplant to 1.4 Day 30. Treatment with
TLI/ATG resulted in no significant change in response to PHA. As-
sessment of T-cell polarization after stimulation with PMA/ionomy-
cin, recipient derived dendritic cells (DCs) or third party DCs
demonstrated a rise of CD8 +T-cells expressing IL-4 and IL-10
consistent with a suppressor phenotype. In summary, both CAM-
PATH and TLI/ATG result in CD4 +T-cell depletion, but TLI/
ATG resulted in persistence of memory cells, relative preservation
of CM as compared to EM and intact response to mitogens. TLI/
ATG therapy was associated with a more modest level of functional
T-cell depletion characterized by Tc2 polarization.169
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CD4 + CD25highFoxP3+ regulatory T cells (Tregs) play a central
role in immunologic homeostasis and are able to induce tolerance af-
ter allogeneic hematopoietic stem cell transplantation (alloPBSCT).
Polyclonal rabbit-anti-human antithymocyte globulins (rATG) are
widely used to prevent and treat Graft-versus-Host-Disease
(GvHD) after alloPBSCT. Their mechanism of action has been
thought to be mainly mediated by CD4+ effector T cell depletion
and complement-dependent lysis. Interestingly, recent in vitro data
have suggested that rATGs might increase the ratio or number of
regulatory T cells. But so far, it is not knownwhether such effects ex-
ist in humans in vivo.
Here, we present the data of a prospective pilot study in which we
analyzed the influence of rATGs on the reconstitution of peripheral
CD4+/CD25high/FoxP3 + Tregs after alloPBSCT.
Ten patients were divided into two groups depending on the re-
quirements of the respective alloPBSCT protocol: those who re-
ceived one type of rATG during conditioning therapy from day -3
to -1 (rATG; n5 6) and those who were conditioned without
rATG administration (non-rATG; n5 4). Patients of the rATG
group received a total dose of either rATG-Fresenius 30 mg/
kgBW (n5 3) or rATG-Genzyme 6 mg/kgBW (n5 3) respectively.
All patients received peripheral hematopoietic stem cells fromHLA-
matched donors and the grafts contained comparable median num-bers of CD3+ and CD34+ in both patient groups (table 1). GvHD
prophylaxis consisted of Mycophenolate Mofetil and Cyclosporine
A in all patients and antiviral prophylaxis was with acyclovir. Periph-
eral blood samples were taken before conditioning and after al-
loPBSCT at distinct time points (day +30, +60, +90 and +150) and
immune cells were analyzed by flow cytometry. An in vitro suppres-
sion assay of d + 150 Tregs from cryopreserved samples was done
with CD4 +CD25+ selected Tregs and CD4 +CD25- selected
CSFE labelled autologous responder T cells.
In summary, we found a more than 3-fold stable increase of rela-
tive Treg numbers in rATG treated patients after alloPBSCT com-
pared to the control. Day + 150 Tregs suppressed the responder cell
proliferation effectively in the in vitro assay.
Taken together, our results rise first evidence that rATG treat-
ment leads to increased, functional active CD4+/CD25high/
FoxP3 + Tregs in humans after allogeneic stem cell transplantation
which supports the thesis that rATG exhibit their immunomodula-
tory activity by additional mechanisms beyond simple cell depletion.
Table 1. Patient characteristics and transplantation parame-
ters
Baseline parameters rATG non-rATGPatients 6 4Age (median) 37 - 68 (61) 48 - 67 (62)Diagnosis MM, MCL, CLL, ALL AML (n5 3), OMFConditioning regimenRIC 5 3Standard 1 1Transplanted cell
numbers x 106/kg
BW recipient,
(median)CD341 PBSC 1.85 - 11.0 (7.6) 4.91 - 9.47 (7.3) p 0.47CD31 T cells 150 - 480 (219) 120 - 540 (175) p 0.38MRD: matched related donor; MUD: matched unrelated donor; RIC:
Reduced Intensity Conditioning (Treosulfan / Fludarabin or Cyclopho-
spamide/Fludarabin or 2 Gy-Total-Body-Irradiation/ Fludarabin); Stan-
dard conditioning (Cyclophosphamide/12 Gy-Total-Body-Irradiation).
BW: body weight; AML: acute myeloid leukaemia; OMF: osteomyelofib-
rosis; CLL: chronic lymphocytic leukaemia; ALL: acute lymphoblastic
leukaemia; MCL: mantle cell lymphoma; MM: multiple myeloma. PBSC:
peripheral blood stem cells. Cellular subpopulations of the transplanted
grafts were calculated to the respective recipients body weight. Statisti-
cal analysis by SPSS.170
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EBV lymphomas (EBV-L) arising postHSCT that persist or recur
following Rituxan therapy are often fatal. We analyzed treatment
with EBV-specific T-cells (EBV-CTL) in 22 patients (pts) who de-
veloped EBV-L following HLA-matched (N5 8) or non-identical
N5 11 T cell depleted (N5 17) or unmodified (N5 3) HSCT or
cord blood grafts (N5 3). All pts had clinical and radiologic evidence
of rapidly growing tumors ofWaldeyer’s ring and/or intestines, liver,
lung or CNS and rising blood levels of EBV DNA. Biopsies showed
B cell, EBV+ lymphoma in 20 pts that were monoclonal (12/12
tested) and usually of donor origin (11/12 tested). Of 22 pts, 14
had failed (N5 10) or recurred (N5 4) following Rituxan treat-
ment. EBV-CTLwere grown from donorT-cells sensitized with au-
tologous EBVBLCL transformed by EBV strain B95.8 (B95.8
EBVBLCL) and tested for specificity, lack of alloreactivity and ste-
rility. Treatment included 3 weekly infusions of EBV-CTL (106 T
